Testosterone Cypionate
FDA-approved product (injectable, injection), marketed as Azmiro, Depo-Testosterone, Testosterone Cypionate.
- Registered studies
- 50+
- Lab records
- 0
- Pathogens at ≥40%
- 1 of 4
Chemical structure
Existing / approved use
Documented · FDA, WHO, ChEMBLApproved for
- Cancer
- Hypogonadism
- Hypogonadotropic hypogonadism
- Klinefelter's syndrome
- Neoplasm
- Orchitis
- Physiological sexual disorder
- Sexual dysfunction
Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗
- WHO therapeutic group
- 3-oxoandrosten (4) derivatives
- Anti-infective classification
- Not classified as an anti-infective.
Repurposing investigation
This medicine is being investigated here for AI-predicted antimicrobial activity against MRSA. It was surfaced computationally for further investigation; it is not an established treatment for this infection.
AI-predicted activity
AI prediction · nothing measured- MRSA56.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
- E. coli32.0% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
- K. pneumoniae26.8% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
- M. tuberculosis24.2% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.
Evidence
Clinical and experimental
Documented evidenceClinical
50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.
Experimental
No evidence found
No laboratory measurement against the four pathogens in the ChEMBL records loaded here.
Docking
Computational · nothing measuredAutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.
Other medicines to investigate
AI prediction · nothing measuredOther repurposing candidates: approved medicines besides Testosterone Cypionate with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.
Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.
- Ozanimod HydrochlorideExisting use: Multiple sclerosis, Relapsing-remitting multiple sclerosis, Ulcerative colitis66.8% AI-predicted activityagainst MRSA7 registered studies
- Micafungin SodiumExisting use: Candidiasis66.8% AI-predicted activityagainst MRSA50+ registered studies
- AbemaciclibExisting use: Breast cancer, Breast carcinoma, Breast neoplasm and 3 more66.4% AI-predicted activityagainst MRSA50+ registered studies
- RisperidoneExisting use: Aggressive behavior, Autism, Bipolar disorder and 4 more66.4% AI-predicted activityagainst MRSA50+ registered studies
- Lazertinib MesylateExisting use: Non-small cell lung carcinoma66.1% AI-predicted activityagainst MRSANo documented evidence found
- Desmopressin AcetateExisting use: Central diabetes insipidus, Diabetes insipidus, Enuresis and 5 more65.8% AI-predicted activityagainst MRSA50+ registered studies
- Terazosin HydrochlorideExisting use: Benign prostatic hyperplasia65.8% AI-predicted activityagainst MRSA41 registered studies
- VemurafenibExisting use: Cancer, Cutaneous melanoma, Melanoma and 2 more65.8% AI-predicted activityagainst MRSA50+ registered studies
- Caspofungin AcetateExisting use: Aspergillosis, Candidemia, Candidiasis and 1 more65.5% AI-predicted activityagainst MRSA50+ registered studies
- VenetoclaxExisting use: Cancer, Chronic lymphocytic leukemia, Neoplasm65.5% AI-predicted activityagainst MRSA50+ registered studies
- Larotrectinib SulfateExisting use: Abdominal Neoplasms, Cancer, Metastasis and 1 more65.4% AI-predicted activityagainst MRSA5 registered studies
- SirolimusExisting use: Adenoma sebaceum, Angiofibroma, Cancer and 5 more65.2% AI-predicted activityagainst MRSA50+ registered studies
Registered studies
A registration describes a study; it does not establish a positive result.
Difluoromethylornithine and High Dose Testosterone With Enzalutamide in Metastatic Castration-Resistant Prostate Cancer
NCT06059118 · start 2023-10-04
Registered record
- Registry ID
- NCT06059118
- Conditions
- Prostate Cancer
- Interventions
- DFMO; testosterone cypionate; Luteinizing hormone-releasing hormone (LHRH) analogue; Enzalutamide
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Recruiting
- Start
- 2023-10-04
- Completion
- 2029-11-30
- Enrolment
- 50
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionProstate CancerInterventionDFMO; testosterone cypionate; Luteinizing hormone-releasing hormone (LHRH) analogue; EnzalutamidePhasePhase 2Registry statusRecruitingHormone Secretion in Transgender Males
NCT04321551 · start 2023-07-01
Registered record
- Registry ID
- NCT04321551
- Conditions
- Transgender; Healthy
- Interventions
- Testosterone Cyp 200Mg/Ml Inj (in Oil); Letrozole
- Study type
- INTERVENTIONAL
- Phase
- Phase 4
- Registry status
- Withdrawn
- Start
- 2023-07-01
- Completion
- 2028-12-31
- Enrolment
- 0
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionTransgender; HealthyInterventionTestosterone Cyp 200Mg/Ml Inj (in Oil); LetrozolePhasePhase 4Registry statusWithdrawnTestosterone Replacement to Alleviate Pain in Postmenopausal Women (TRAPP Trial)
NCT04895306 · start 2022-11-15
Registered record
- Registry ID
- NCT04895306
- Conditions
- Pain; Opioid Use; Androgen Deficiency; Back Pain
- Interventions
- Testosterone Cypionate; Placebo
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Completed
- Start
- 2022-11-15
- Completion
- 2026-03-27
- Enrolment
- 36
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionPain; Opioid Use; Androgen Deficiency; Back PainInterventionTestosterone Cypionate; PlaceboPhasePhase 2Registry statusCompletedEffect of Dose Fractionation of Testosterone Cypionate on Transgender Men with Erythrocytosis
NCT05487794 · start 2022-09-01
Registered record
- Registry ID
- NCT05487794
- Conditions
- Testosterone; Transsexualism; Hematologic Diseases
- Interventions
- Testosterone Cypionate 100 MG/ML
- Study type
- INTERVENTIONAL
- Phase
- Not applicable
- Registry status
- Completed
- Start
- 2022-09-01
- Completion
- 2024-12-17
- Enrolment
- 46
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionTestosterone; Transsexualism; Hematologic DiseasesInterventionTestosterone Cypionate 100 MG/MLPhaseNot applicableRegistry statusCompletedCan Testosterone Accelerate Injury Recovery After Arthroscopic Rotator Cuff Repair
NCT04345666 · start 2021-08
Registered record
- Registry ID
- NCT04345666
- Conditions
- Rotator Cuff Tears
- Interventions
- Testosterone cypionate; Placebos
- Study type
- INTERVENTIONAL
- Phase
- Phase 2 / Phase 3
- Registry status
- Withdrawn
- Start
- 2021-08
- Completion
- 2023-01
- Enrolment
- 0
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionRotator Cuff TearsInterventionTestosterone cypionate; PlacebosPhasePhase 2 / Phase 3Registry statusWithdrawnExtreme Bipolar Androgen Therapy With Darolutamide and Testosterone Cypionate in Patients With Metastatic Castration-Resistant Prostate Cancer (ExBAT Trial)
NCT04558866 · start 2021-06-09
Registered record
- Registry ID
- NCT04558866
- Conditions
- Prostate Cancer
- Interventions
- Testosterone Cypionate; Darolutamide
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Completed
- Start
- 2021-06-09
- Completion
- 2024-04-02
- Enrolment
- 51
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionProstate CancerInterventionTestosterone Cypionate; DarolutamidePhasePhase 2Registry statusCompletedLocomotor Training With Testosterone to Promote Bone and Muscle Health After Spinal Cord Injury
NCT04460872 · start 2021-01-31
Registered record
- Registry ID
- NCT04460872
- Conditions
- Spinal Cord Injury; Spinal Cord Injuries; Trauma, Nervous System; Wounds and Injury; Central Nervous System Diseases; Spinal Cord Diseases; Gonadal Disorders; Endocrine System Diseases; Hypogonadism; Genital Diseases, Male; Spinal Cord Trauma; Injuries, Spinal Cord; Walking, Difficulty; Gait Disorders, Neurologic; Locomotion Disorder, Neurologic; Wounds and Injuries; Nervous System Diseases; Testosterone Deficiency; Androgen Deficiency; Hormone Deficiency
- Interventions
- Testosterone Enanthate; Locomotor Training
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Recruiting
- Start
- 2021-01-31
- Completion
- 2026-06-30
- Enrolment
- 21
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionSpinal Cord Injury; Spinal Cord Injuries; Trauma, Nervous System; Wounds and Injury +16 moreInterventionTestosterone Enanthate; Locomotor TrainingPhasePhase 2Registry statusRecruitingPerioperative Testosterone Replacement Therapy for the Improvement of Post-Operative Outcomes in Patients With Low Testosterone
NCT04731376 · start 2021-01-25
Registered record
- Registry ID
- NCT04731376
- Conditions
- Hypogonadism; Malignant Urinary System Neoplasm; Urinary System Disorder; Urinary System Neoplasm
- Interventions
- Best Practice; Quality-of-Life Assessment; Questionnaire Administration; Testosterone Cypionate
- Study type
- INTERVENTIONAL
- Phase
- Phase 1
- Registry status
- Active not recruiting
- Start
- 2021-01-25
- Completion
- 2026-12-31
- Enrolment
- 56
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionHypogonadism; Malignant Urinary System Neoplasm; Urinary System Disorder; Urinary System NeoplasmInterventionBest Practice; Quality-of-Life Assessment; Questionnaire Administration; Testosterone CypionatePhasePhase 1Registry statusActive not recruitingEffect of Transgender Therapy on Muscle, Fat and Tissue Receptors
NCT04551144 · start 2020-10-06
Registered record
- Registry ID
- NCT04551144
- Conditions
- Gender Incongruence; Transgenderism
- Interventions
- testosterone cypionate; Estradiol Valerate
- Study type
- OBSERVATIONAL
- Phase
- Not recorded
- Registry status
- Terminated
- Start
- 2020-10-06
- Completion
- 2023-01-18
- Enrolment
- 4
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionGender Incongruence; TransgenderismInterventiontestosterone cypionate; Estradiol ValeratePhaseNot recordedRegistry statusTerminatedBiomarker Analysis of Castration-resistant Prostate Cancer Undergoing Bipolar Androgen Therapy
NCT04424654 · start 2020-09-22
Registered record
- Registry ID
- NCT04424654
- Conditions
- Prostate Cancer
- Interventions
- Testosterone cypionate
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Completed
- Start
- 2020-09-22
- Completion
- 2022-07-01
- Enrolment
- 20
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionProstate CancerInterventionTestosterone cypionatePhasePhase 2Registry statusCompletedSequential Testosterone and Enzalutamide Prevents Unfavorable Progression
NCT04363164 · start 2020-08-19
Registered record
- Registry ID
- NCT04363164
- Conditions
- Castration Resistant Metastatic Prostate Cancer
- Interventions
- Testosterone cypionate; Enzalutamide; Testosterone enanthate
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Recruiting
- Start
- 2020-08-19
- Completion
- 2028-07
- Enrolment
- 150
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionCastration Resistant Metastatic Prostate CancerInterventionTestosterone cypionate; Enzalutamide; Testosterone enanthatePhasePhase 2Registry statusRecruitingA Comparison of Side Effects in Hypogonadal Men Treated With Natesto Versus Testosterone Injections
NCT04439799 · start 2020-08-07
Registered record
- Registry ID
- NCT04439799
- Conditions
- Hypogonadism, Male
- Interventions
- Testosterone Cypionate 200 Mg/ML; Intranasal Testosterone
- Study type
- INTERVENTIONAL
- Phase
- Phase 4
- Registry status
- Completed
- Start
- 2020-08-07
- Completion
- 2023-02-09
- Enrolment
- 81
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionHypogonadism, MaleInterventionTestosterone Cypionate 200 Mg/ML; Intranasal TestosteronePhasePhase 4Registry statusCompletedGeneration of Biological Samples Positive to Testosterone for Anti-doping Control
NCT04207684 · start 2020-02-04
Registered record
- Registry ID
- NCT04207684
- Conditions
- Healthy Volunteers
- Interventions
- Testosterone injection
- Study type
- INTERVENTIONAL
- Phase
- Phase 1
- Registry status
- Completed
- Start
- 2020-02-04
- Completion
- 2020-02-26
- Enrolment
- 4
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionHealthy VolunteersInterventionTestosterone injectionPhasePhase 1Registry statusCompletedImproving Quality of Life of Prostate Cancer Survivors With Androgen Deficiency
NCT03716739 · start 2019-03-19
Registered record
- Registry ID
- NCT03716739
- Conditions
- Prostate Cancer
- Interventions
- Testosterone Cypionate 100 MG/ML; Placebo
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Completed
- Start
- 2019-03-19
- Completion
- 2025-07-16
- Enrolment
- 136
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionProstate CancerInterventionTestosterone Cypionate 100 MG/ML; PlaceboPhasePhase 2Registry statusCompletedA Bioequivalence Study of Testosterone Cypionate in Hypogonadal Males
NCT03792477 · start 2019-01-19
Registered record
- Registry ID
- NCT03792477
- Conditions
- Hypogonadism
- Interventions
- Test formulation; Reference formulation
- Study type
- INTERVENTIONAL
- Phase
- Phase 1
- Registry status
- Completed
- Start
- 2019-01-19
- Completion
- 2020-04-02
- Enrolment
- 74
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionHypogonadismInterventionTest formulation; Reference formulationPhasePhase 1Registry statusCompleted